METAGENICS OSTEOPOROSIS CLAIMS FOR BONE BUILDER SUPPLEMENT CHALLENGED BY FTC
This article was originally published in The Tan Sheet
Executive Summary
METAGENICS OSTEOPOROSIS CLAIMS FOR BONE BUILDER SUPPLEMENT CHALLENGED BY FTC in an administrative complaint announced by the Federal Trade Commission Aug. 19. In a proposed order accompanying the complaint, FTC declared that San Clemente, Calif.-based Metagenics must "cease and desist from representing" that Bone Builder calcium supplement or any other product "halts, prevents or treats osteoporosis"; "builds bone or increases bone thickness"; and "restores lost bone" without adequate substantiation.